pdufa.bio
Home › CRL letters › June 2026

FDA complete response letters, June 2026

Page updated ·next FDA decision on the calendar ·Data as of Nov 10, 2026 12:55 AM ET

The FDA's public release of complete response letters holds 9 letters dated June 2026 (openFDA, last updated 2026-08-26). Of the 21 FDA decisions on PDUFA goal dates pdufa.bio tracked in June 2026, 4 were Complete Response Letters.

Released by the FDA, dated June 2026 · 9

Letter dateCompanyApplicationopenFDA statusLetter
2026-06-29Ipsen Biopharm Ltd.BLA 761311Unapprovedletter (PDF)
2026-06-29Unicycive Therapeutics Inc.NDA 218607Unapprovedletter (PDF)
2026-06-26Evergreen Theragnostics, Inc.NDA 216900Unapprovedletter (PDF)
2026-06-26Swedish Orphan Biovitrum AB (publ)BLA 761438Unapprovedletter (PDF)
2026-06-23Tanvex BioPharma USA, Inc.BLA 761266Unapprovedletter (PDF)
2026-06-20Achieve Life Sciences, Inc.NDA 218995Unapprovedletter (PDF)
2026-06-15Tris Pharma, Inc.NDA 220138Unapprovedletter (PDF)
2026-06-10Bridge Regulatory Affairs, LLCNDA 218600Unapprovedletter (PDF)
2026-06-04Xspray Pharma ABNDA 217644Unapprovedletter (PDF)

Complete Response Letters among decisions pdufa.bio tracked · 4

FDA actionTickerDrugSource
2026-06-30UNCYOxylanthanum Carbonate (OLC)decision page
2026-06-26LNTHLNTH-2501 (Gallium-68 edotreotdecision page
2026-06-22ACHVCytisinicline - (ORCA-3)decision page
2026-06-02CINGCTx-1301 (fixed dose, pediatridecision page
A Complete Response Letter is the FDA's notice that it will not approve an application in its current form; it is not a permanent rejection, and the sponsor can resubmit. The two counts come from different records and are not added together. ← May 2026 · July 2026 → · all released letters · every CRL decision we tracked